[Essential thrombocythemia: therapy with alpha interferons].
Gugliotta
L
L
Istituto di Ematologia L. e A. Seràgnoli, Università di Bologna.
Catani
L
L
Vianelli
N
N
Mattioli Belmonte
M
M
Cascione
M L
ML
Bendani
M
M
Fanin
R
R
Michieli
M G
MG
Baccarani
M
M
Tura
S
S
D000917:Antibody Formation; D004341:Drug Evaluation; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007370:Interferon Type I / Q000276:immunology / Q000627:therapeutic use; D016898:Interferon-alpha / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D008533:Megakaryocytes / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D011994:Recombinant Proteins; D013920:Thrombocythemia, Essential / Q000628:therapy*
D007155:Immunologic Factors; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins
Trombocitemia essenziale: la terapia con interferoni alpha.